Investor RelationsCOVID-19
  1. Home
  2. Medical Imaging
  3. Molecular Imaging
  4. PETNET radiopharmaceuticals

PETNET SolutionsDelivering a broad portfolio of PET radiopharmaceuticals to advance patient outcomes

PETNET Solutions Inc, A Siemens Healthineers Company, reliably delivers PET radiopharmaceuticals via the largest network of cyclotron-equipped radiopharmacies globally. Supported by experts averaging more than 20 years of industry experience, PETNET customers unlock access to a wide array of tracers, customized data analytics, and educational resources to drive growth.

Discover more than FDG imaging 

1/3
Beta-amyloid and tau PET imaging01
POSLUMA01
PETNET Solutions01
PETNET neuro map

Map of active beta-amyloid and tau PET imaging production sites. This map is intended as a general representation of PETNET’s potential ground coverage within 150 mile radius of each radiopharmacy site. PETNET also delivers doses by air for specific locations beyond ground service areas.  

For accurate service information for your specific location, please contact our Customer Care Team at +1 (877) 473-8638 or customercare@petnetsolutions.com.  

Beta-amyloid and tau PET imaging

Early confirmation of the presence of Alzheimer's Disease pathology can be important. 
PETNET Solutions offers the broadest portfolio of PET tracers for imaging biomarkers of neurodegenerative disease and is equipped to help your imaging center launch their Neurology Imaging Program.

PETNET neuro map
PETNET posluma map no radius
PETNET Solutions delivery map
1/3

Case study

(Left to right) Shanon Kriz, regional director, Radiation Services, Sentara Health; Charlie Joyce, PETNET Solutions regional sales director; and Frances Vargas, regional PET/CT imaging manager, Sentara Health

Enhancing healthcare excellence: improving patient access and driving business growth with PETNET Solutions

As the patient demand for PET imaging grows, imaging centers need a reliable PET radiopharmaceutical partner to support them. Read the case study to learn how Sentara Health improves patient access and drives business growth with PETNET Solutions.

"PETNET understands the need, the urgency, and we both have the common goal of servicing our patients."
Frances Vargas 
Frances Vargas 
Regional PET imaging  manager for Sentara Health 

Our portfolio

Broadest portfolio of PET radiopharmaceuticals  

Whether your focus is on clinical care or investigational research, PETNET offers the broadest portfolio of PET radiopharmaceuticals manufactured and delivered from a single supplier:


Axumin® and POSLUMA® are registered trademarks owned or licensed by Blue Earth Diagnostics.  
Cerianna™ is a trademark owned or licensed by GE HealthCare Technologies Inc., its subsidiaries and/or affiliates.  
AMYVID® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
TAUVID™ is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. 

Who we are

PETNET Solutions Inc.  

PETNET operates in the USA, the UK, France, and India

Delivering from the largest global PET radiopharmacy network

With 47 cyclotron-powered radiopharmacies around the globe, PETNET is the largest supplier of positron emission tomography (PET) radiopharmaceuticals. We manufacture and deliver more than 1,473,000 doses1 to more than 2,800 imaging centers1 each year. In the United States alone, we deliver at least one product to 92% of PET imaging centers.2

Contract manufacturer of choice 

Our global footprint, quality leadership, and broad portfolio expertise make us the ideal choice for IP holders working to bring new agents to market. 

We have demonstrated leadership in the PET regulatory space. We submitted and obtained FDA approval of 18F-FDG well in advance of industry requirements and continue to work closely with the FDA as new technology appears and the PET industry evolves. 

And as a key part of Siemens Healthineers Molecular Imaging, we have a direct line into front-line research and development in the world of molecular imaging. 

PETNET pharmacy illustrations

Clinical trial guidance 

Customers in the United States have unique opportunities to participate in clinical trials with the support of PETNET. We are always collaborating with pharmaceutical companies to research new agents and submit drug applications. In addition to providing access to radiopharmaceuticals, we provide the training and support needed to participate in clinical trials across the United States.

Seamless delivery

More than 12 million doses delivered since 2011 

PETNET maintains a dose fulfilment rate of >99% through our integrated network of radiopharmacies. We know it can be challenging to maintain patient schedules, minimize wait times, and provide timely results to referring physicians without PET tracer delivery you can count on. 

 

PETNET cyclotron

Engineered 
reliability

Heavy investments in equipment design and redundancy increase uptime and output, upgrade cyclotron RF technology, and advance targetry, ion output, and control systems technologies.

PETNET pharmacy illustration

Proven on-time 
delivery

We use automated production, route optimization, and GPS technology to support on-time delivery in the US.

PETNET exemplifies high quality

Leading high quality production

Updates to our pharmacy information management system help ensure product quality and patient safety for customers within the US.

PETNET opens a new radiopharmacy site in Chicago.

Ongoing infrastructure investments

We are committed to continuing to invest heavily in our radiopharmacy sites to increase capacity, output, and operational efficiency. Last year, we opened 2 replacement radiopharmacy sites (and upgraded equipment, including cyclotrons, in several others).

Read about our ongoing investments

Expert support

PETNET's knowledgeable staff averaging more than 20 years of industry experience supports your imaging practice and encourages growth. You can rely on our high performance customer care, pharmacy, and sales teams for ordering and scheduling support, market development, and strategic account engagement.

 

1
FY23 total dose delivery, data on file
2

Based on 2020 IMV data and internal records

Axumin® and POSLUMA® are registered trademarks owned or licensed by Blue Earth Diagnostics.
Cerianna™ is trademark owned or licensed by GE HealthCare Technologies Inc., its subsidiaries and/or affiliates. 
AMYVID® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
TAUVID™ is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.